In lung cancer, it was reported that a combination of EGCG and the NF-κB inhibitor BAY11-7082 had a synergistic effect in reducing lung cancer cell proliferation by suppressing NF-κB signaling, both in vitro and in vivo, also EGCG alone inhibits lung cancer cell proliferation by suppressing NF-κB signaling [85]. The gene discussed is NFKB1; the disease is lung carcinoma.